Evozyne
AI-engineered proteins for immune-mediated disease
Chicago, United States · Founded 2020 · $135.2M raised
- Headquarters
- Chicago, Illinois
- Employees
- 51–200
- Founded
- 2020
- Business Model
- B2B
- Website
- evozyne.com
- Total Funding
- $135.2M
- Last Round
- $81.0M Series BSep 2023
- Rounds
- 2
About
Evozyne is an AI-native biotech company that designs novel engineered protein therapeutics to address immune-mediated diseases. Founded by Paragon Biosciences, the company uses generative deep learning and high-throughput biology to create proteins with mechanisms that natural evolution never produced. Based in Chicago, Evozyne collaborates with partners including NVIDIA to accelerate the path from protein design to clinical application.
Summary
Evozyne is an Artificial Intelligence company based in Chicago, United States, founded in 2020. It has raised $135.2M in total across 2 rounds, most recently a $81.0M Series B round in Sep 2023. Investors include OrbiMed, Fidelity Management and nVentures.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...